Orakl Oncology Raises $34 Million for AI Drug Prediction

By Daniel Okafor

Orakl Oncology secured a $34 million oversubscribed Series A, lifting total funding to $50 million, Norrsken VC said on November 12, 2026.

Norrsken VC co-led the round alongside Singular. Norrsken listed new investors InfraVia, Serena, the Patient Autonome Fund managed by Bpifrance, teampact.ventures and Plug and Play. Existing backers Verve Ventures, Speedinvest and HCVC also joined the round.

What will the $34 million fund?

Norrsken said the proceeds will support five priorities:

• Expand Orakl’s dataset and AI research team.
• Increase data generation fivefold.
• Establish teams in the US and UK.
• Deploy predictions across more than 10 drug programs.
• Discover and validate drug co-targets using patient biology and experimental screens.

Orakl also plans to extend its work beyond colorectal and pancreatic cancers into lung and gastric cancers.

How does Orakl generate patient-derived data?

Orakl says it was founded in 2023 as a spin-out of Gustave Roussy. It grows patient-derived tumor organoids, which are laboratory models of individual patients’ cancers, and screens them against drugs.

Its platform overview says results combine genomic, transcriptomic and phenotypic data with longitudinal clinical histories. Orakl uses those inputs to build a multimodal dataset for its predictive systems.

Orakl divides its biopharma products into two systems:

• O-Predict anticipates trial endpoints, including tumor response, progression-free survival and overall survival. It also identifies likely-responder biomarkers, assesses drug combinations and compares benefit-risk profiles.
• O-Target focuses on therapeutic-target discovery.

Norrsken calls the resulting patient cohorts “virtual cancer patients.” Norrsken says drug-response measurements must come from patient samples, laboratory infrastructure and hospital partnerships, rather than existing databases.

Each experiment adds proprietary data connecting patient biology, clinical information and observed drug responses, according to Norrsken.

What does the SCOPE preprint show?

Orakl reports 90% accuracy for prospective predictions of individual patient responses across more than 30 clinical trials.

A separate April 2026 preprint, co-authored by Orakl staff, provides arm-level results for SCOPE, the Screening-to-Clinical Outcome Prediction Engine. The document marks the work as early-stage research that may not yet have been peer reviewed.

SCOPE trained on 54 treatment lines from 52 patients with metastatic colorectal or pancreatic cancer, using matched clinical data and organoid screens covering nine compounds.

For trial outcomes, SCOPE generated synthetic patient profiles from published eligibility criteria and matched them to a biobank of 81 patient-derived organoid lines. External validation covered 32 treatment arms from 23 published trials.

• For predicted median progression-free survival, the authors reported an R² of 0.85 and a mean absolute error of 0.82 months. Progression-free survival measures the time patients live without disease progression.
• For objective response rate, the share of patients with a measured tumor response, the authors reported an R² of 0.71 and a mean absolute error of 7.3 percentage points.

The preprint’s authors report that combining organoid and clinical data significantly outperformed either data type alone. SCOPE also selected the superior treatment arm in seven of eight head-to-head comparisons.

Before Phase III data became available, the preprint describes a prospective SCOPE application to daraxonrasib. The platform predicted superiority over standard chemotherapy in KRAS-mutant metastatic pancreatic cancer.

How large is Orakl’s commercial pipeline?

Norrsken reports that 18 of the world’s 20 largest pharmaceutical companies have joined Orakl’s commercial pipeline just over a year after its commercial launch.

Norrsken said the figure counts pipeline participation rather than signed customers. The investor also said Orakl’s first pharmaceutical engagements have become multi-year collaborations.

More than 15 additional cancer centers across Europe, North America and Asia are in contract negotiations with Orakl, according to Norrsken.

Orakl has more than 40 employees, and 30% hold PhDs, Norrsken said. Its co-founders are CEO Fanny Jaulin, CTO Gustave Ronteix and COO Diane-Laure Pagès. Norrsken said their backgrounds span cancer biology, AI, data science, oncology and hospital partnerships.

What must Orakl prove next?

The next phase will test whether Orakl can extend its patient-derived data model into additional cancers while turning broad pharmaceutical interest into more multi-year drug-development collaborations, Norrsken said.

The Series A supplies the capacity for that test through fivefold data generation, new US and UK teams and deployment across more than 10 drug programs.